UBS has initiated coverage on NeuroPace Inc, assigning a Buy rating with a price target of $17.00, citing strong growth potential driven by its unique RNS technology for drug-resistant epilepsy. The company reported a record $21.1 million in Q3 revenue, a 28% increase year-over-year, and anticipates a revenue range of $78 million to $80 million for 2024. With a projected 22% CAGR from 2024 to 2029, NeuroPace is positioned for significant market expansion, particularly in the second half of 2025.